Business Wire

ERBE-ELEKTROMEDIZIN

Share
Erbe Elektromedizin to acquire Maxer Endoscopy

An investment to strengthen our operating room presence

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005418/en/

“This acquisition reflects our determination to become a solution provider for surgeries and procedures where visualization is critical. We will offer holistic solutions, from visualization to therapy. Entering into the world of fluorescence imaging systems is the logical first step to provide the required added value to our customers", according to Christian O. Erbe, CEO & President at Erbe Elektromedizin GmbH. Maxer’s highly innovative product portfolio combined with Erbe’s energy-emitting high-tech products will allow existing unmet user needs to be addressed.

Better vision makes better surgery

Maxer’s prime innovation focus is on the development of high-end visualization. The technology delivers bright and pin-sharp multi-spectral images for NIR fluorescence-guided surgery and regular white light images. Now, Erbe will be able to offer best-in-class performance with 4K and fluorescence-guided systems in endoscopy as well as for open surgeries.

In 2020, Maxer and its partners, the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM), won the first prize of the German Medical Award in the “Innovation Product” category for its Atlas project. The plan is to provide the surgeon with a “GPS system” that enables the performance of advanced laparoscopic surgeries with increased surgical precision. This will help to reduce complications and risks during oncological surgeries and increase quality of patient life.

A perfect match with excellent growth prospects

The philosophy and values at Maxer are similar to Erbe’s. The company has a remarkable track record of high-tech devices in the last seven years and is perfectly positioned to master future opportunities, such as augmented reality-guided surgery. A broad minimal invasive instrument portfolio will be an ideal match to Erbe’s existing offering.

“Wonderful instruments and multi-spectral imaging systems will get access to the market through our strong sales force and our distribution partners in more than 110 countries”, says Marcus C. Felstead, CMO at Erbe.

“This acquisition will allow the company to speed up delivery of breakthrough innovations in areas of image-guided surgery,” states Shirish Joshi, Managing Director at Maxer.

Erbe was advised by ConAlliance (Mergers & Acquisitions) and RWT Reutlingen (Legal and Financial).

Our vision

The combination of electrosurgery and imaging will provide added value by processing and combining data using AI. This will lead to new treatment options and enhance patient safety. The best of both worlds.

About Maxer

Located in the Tuttlingen medical endoscopy cluster in Germany, Maxer is specialized in minimally invasive surgery (MIS). Maxer manufactures a wide range of endoscopic systems and instruments for laparoscopy, hysteroscopy, urology, pediatric surgery, arthroscopy, spine endoscopy and ENT surgery. Maxer’s core strength has been in the development of top-of-the-line visualization technologies. Maxer is partnering with the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM) to bring computer-assisted surgery to operating rooms.

About Erbe

Erbe Elektromedizin GmbH develops, manufactures and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.

Fields of activity

  • Imaging
  • Endoscopy
  • Electrosurgery
  • Plasma surgery
  • Thermofusion
  • Hydrosurgery
  • Cryosurgery

An international network

  • 15 subsidiaries in Europe, America and Asia
  • 1 representative office
  • Erbe is active in 110 national markets

The Erbe workforce

  • Over 1,000 employees worldwide
  • Some 700 of them in Germany

Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tuebingen, Germany
http://www.erbe-med.com
info@erbe-med.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LambdaTest and SVAM International Inc. Announce Partnership to Transform Quality Engineering for Businesses26.11.2025 18:00:00 CET | Press release

The alliance empowers enterprises with accelerated SDLC cycles, reduced testing effort, and modern AI-driven digital transformation capabilities LambdaTest, a Gen-AI native quality engineering platform, announced a partnership with SVAM International, Inc., a global leader in digital transformation services. This strategic alliance marks a significant step forward in their mission to transform quality engineering for businesses worldwide. The partnership allows LambdaTest to extend its AI-native quality engineering capabilities into SVAM’s extensive digital transformation ecosystem. By integrating with SVAM’s experience in large-scale application development, testing, and delivery across major New York State and City agencies, as well as their platform expertise across Salesforce, ServiceNow, and Dynamics365, LambdaTest will empower more enterprises to modernize their software delivery pipelines. With LambdaTest’s intelligent test orchestration and execution engine at the core, teams c

GLORY Acquires Remaining Equity Shares in Acrelec Group26.11.2025 16:11:00 CET | Press release

Acrelec becomes a wholly owned subsidiary of Glory Glory Global Solutions (International) Ltd, a wholly-owned subsidiary of GLORY Ltd. [TYO:6457], has announced the acquisition of the remaining equity shares in Acrelec Group SAS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251126039437/en/ Acrelec is a global technology company focused on reinventing the customer experience for restaurant and retail brands. Leveraging decades of software, hardware and service expertise, the company develops and integrates new platforms that increase customer engagement, optimize efficiency and improve operations. With over 120,000 installations across more than 70 countries, Acrelec counts many of the world’s best-known restaurant mega-brands among its customers. We announce that Jalel Souissi has left the Acrelec Group following the completion of the recent share acquisition. Jalel Souissi has played a pivotal role in the development and

Andersen Global styrker sin platform i Tyrkiet med tilføjelsen af medlemsvirksomhed26.11.2025 14:49:00 CET | Pressemeddelelse

Andersen Global udvider sin tilstedeværelse i Tyrkiet, efter at Celen Corporate Property Valuation & Counseling Inc. bliver til Andersen i Tyrkiet, hvilket udvider de kompetencer, der tilbydes under Andersen-brandet i landet. Det Istanbul-baserede firma blev stiftet i 1995 og ledes af Managing Partner Guniz Celen med en bred vifte af ydelser til både nationale og internationale kunder. Med ekspertise inden for finansiering af fast ejendom, værdiansættelse af materielle og immaterielle aktiver samt formueforvaltning leverer den tyrkiske afdeling af Andersen løsninger, der understøtter komplekse finansielle beslutninger for kunder i mere end 18 lande. “Vores mission har altid været at levere løsninger på de mest komplekse udfordringer inden for ejendoms- og investeringssektoren,” sagde Guniz. “At blive en del af Andersen-brandet styrker vores kompetencer som en betroet rådgiver og giver os adgang til globale ressourcer, hvilket gør os i stand til at skabe endnu større langsigtet værdi fo

Cegid Acquires Shine to Accelerate the Path of Becoming Europe's Leading Financial Copilot for SMBs and Accountants26.11.2025 14:00:00 CET | Press release

Transformative combination creates a powerhouse for SMBs and accountants, empowering businesses across Europe by integrating leading suites of e-invoicing, digital accounting, business accounts and payments, and HR solutions into a unified platform. Cegid, a European leader in cloud software for finance, accounting, HR, and retail software, and Shine, a fast-growing European fintech unicorn providing digital business accounts and payments, e-invoicing, accounting, and payroll software to small businesses across Europe, announced today that the companies have entered a definitive agreement to join forces to form a European champion and become a leading provider of software for businesses and their accountants. This transformational combination will create the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe – bringing together market-leading capabilities in e-invoicing, accounting, digital business accounts and payments, ta

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma26.11.2025 12:00:00 CET | Press release

If approved, sonrotoclax will become the first BCL2 inhibitor for R/R MCL in the U.S., addressing a high unmet need in an aggressive cancerSonrotoclax previously received Breakthrough Therapy Designation based on clinically meaningful, rapid responses in R/R MCLBeOne Medicines will present the data supporting the NDA and Priority Review for the first time at ASH 2025 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to a New Drug Application (NDA) for sonrotoclax, a next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase (BTK) inhibitor. “Sonrotoclax is advancing with remarkable speed, from Breakthrough Therapy Designation to Priority Review, all within a short window,” said Lai Wang, Ph.D., Global Head of R&D at BeOne.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye